Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lin BioScience Inc.

linbioscience.weebly.com

Latest From Lin BioScience Inc.

UK Charity Starts Early-Stage Clinical Studies Of Lilly's Cdc7 Inhibitor

The drug development arm of the UK charity, Cancer Research UK, has started early clinical development of potentially a new type of anticancer, a Cdc7 inhibitor, discovered by Eli Lilly, in an effort that could boost traction in this new area of research.

Clinical Trials Cancer

Start-Up Quarterly Statistics: Early Funding Declined, But Deal Dollars Flowed

A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.

StartUps and SMEs Financing

Tech Transfer Roundup: Ohio State Turns To Industry Exec To Optimize Assets Before A Deal

Jeffrey Patrick joins Ohio State's effort to develop cancer drugs from internal research, bringing a biopharma viewpoint to optimizing such programs before the deal-making effort starts. Plus, the EMA sets a framework for academic interaction, and more tech transfer news.

Deals StartUps and SMEs

Tech Transfer Roundup: Repeat Business As Boehringer, Vanderbilt Collaborate Further On KRAS

This month's roundup also records a second tie-up between Florida State and Spotlight Innovations, while Taiwan's Lin Biosciences licenses global rights to a CDC7 kinase inhibitor from Columbia and Memorial Sloan Kettering.

Deals StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Taiwan
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Lin BioScience Inc.
  • Senior Management
  • Tom Lin, PhD, CEO
    Irene Wang, PhD, Dir., Bus. Dev. & R&D
  • Contact Info
  • Lin BioScience Inc.
    Phone: 2 8780 5008
    12F., No.68, Sec.5, Zhongxiao E. Rd.
    Xinyi Dist.
    Taipei City, CA 110
    Taiwan
Advertisement
Advertisement
UsernamePublicRestriction

Register